REGISTER
DESTINY-Breast05 Marks Major HER2+ Adjuvant Breakthrough
The discussion highlights why Breaking Results from DESTINY-Breast05 deserves closer attention. By organizing evidence on DESTINY, HR, IDFS, it turns scattered results into practical conclusions for clinicians and patients.

On the afternoon of October 18 (local time), Dr. Charles E. Geyer from the University of Pittsburgh, USA, presented the study titled “Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05” (Abstract #: LBA1) during the Presidential Symposium.

T-DXd Provides a More Effective Adjuvant Treatment Option for High-Risk HER2+ Breast Cancer with Non-pCR After Neoadjuvant Therapy

The DESTINY-Breast05 study is a global, multicenter, randomized, open-label, Phase III clinical trial designed to evaluate the efficacy and safety of adjuvant trastuzumab deruxtecan (T-DXd) compared to trastuzumab emtansine (T-DM1) in patients with high-risk HER2-positive (HER2+) primary breast cancer who have residual invasive disease after neoadjuvant therapy.

Efficacy Results

The study enrolled approximately 1,600 patients, randomly assigned to receive either T-DXd (5.4 mg/kg, Q3W) or T-DM1 (3.6 mg/kg, Q3W) for 14 cycles. Baseline characteristics were generally balanced between the two groups.

Figure 1. DESTINY-Breast05 Study Design

The results showed that the 3-year invasive disease-free survival (IDFS) rate was 92.4% in the T-DXd group, significantly higher than 83.7% in the T-DM1 group (HR = 0.47; 95% CI, 0.34–0.66; P < 0.0001).

Subgroup analyses indicated that T-DXd provided significant benefit even in patients at high risk of recurrence, including those who were initially inoperable, hormone receptor-negative (HR−), or had residual positive axillary lymph nodes after neoadjuvant therapy. Furthermore, compared to T-DM1, patients treated with T-DXd showed lower incidences of both distant recurrence (including central nervous system recurrence) and locoregional recurrence.

Figure 2. IDFS Data from DESTINY-Breast05

Figure 3. Subgroup Analysis of IDFS in DESTINY-Breast05

For key secondary endpoints, the 3-year disease-free survival (DFS) rate was also significantly higher in the T-DXd group (92.3%) compared to the T-DM1 group (83.5%) (HR = 0.47; 95% CI, 0.34–0.66).

In terms of distant recurrence-free interval (DRFI), the 3-year DRFI rates were 93.9% for T-DXd and 86.1% for T-DM1 (HR = 0.49; 95% CI, 0.34–0.71). Additionally, the 3-year brain metastasis-free interval (BMFI) rates were 97.6% for T-DXd and 95.8% for T-DM1 (HR = 0.64; 95% CI, 0.35–1.17). The overall survival (OS) data are not yet mature.

Figure 4. DFS Data from DESTINY-Breast05

Figure 5. DRFI, BMFI, and OS Data from DESTINY-Breast05

Safety Profile

Regarding safety, over 72% of patients in both groups completed the planned treatment. The incidence of Grade ≥3 adverse events was 50.6% in the T-DXd group and 51.9% in the T-DM1 group.

No new safety signals were identified for T-DXd. Adjudicated drug-related interstitial lung disease (ILD)/pneumonitis was mostly Grade 1–2, with Grade ≥3 events occurring in only 1.1% of patients. This risk was considered manageable with appropriate monitoring and timely intervention. Overall, T-DXd demonstrated a manageable and tolerable safety profile.

Figure 6. Overall Safety Summary for DESTINY-Breast05

Dr. Charles E. Geyer concluded: “For patients with high-risk HER2-positive early breast cancer who have residual invasive disease after neoadjuvant therapy, adjuvant T-DXd demonstrated superior IDFS and DFS benefits compared with T-DM1. These results are both statistically significant and clinically meaningful, and T-DXd has the potential to become a new standard of care for this population.”

Reference

  • Charles E. Geyer, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. 2025 ESMO LBA1.

0
0
Loading